A Food and Drug Administration advisory committee today recommended the agency authorize Moderna’s COVID-19 two-dose vaccine for children aged 6 months through 5 years old and Pfizer’s three-dose COVID-19 vaccine for children aged 6 months through 4 years old. Based on the scientific evidence available, the committee agreed that each vaccine’s benefits outweigh its risks in these age groups. Yesterday, the committee also voted to recommend FDA authorize Moderna’s vaccine for children age 6-17, which would provide an alternative to the currently authorized Pfizer vaccine for this age group.

Before vaccinations can begin, FDA must authorize and the Centers for Disease Control and Prevention recommend the vaccines for these age groups. CDC’s Advisory Committee on Immunization Practices could consider the issue as soon as June 17-18.
 

Related News Articles

Headline
The departments of Health and Human Services and Defense yesterday announced an agreement to purchase at least 105 million doses of a Pfizer omicron-…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…
Headline
The Food and Drug Administration today authorized Moderna’s COVID-19 vaccine for children aged 6 months through 17 years old and Pfizer’s COVID-19 vaccine for…